Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paxlovid plus conventional therapy in older adults with COVID-19
ChiCTR2200060700Phase 4Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Nucleic acid shedding time. Started Jun 2022; status: recruiting.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200060700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060700.